Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.
Related Posts
Cohance to further invest USD 18M to strengthen its ADC strategy
Cohance Lifesciences today announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aruka Bio. Both the transactions will be funded through internal accruals.
Explained: What Donald Trump’s up to 200% pharma tariffs mean for Indian investors
Donald Trump’s announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be limited, citing India’s manufacturing cost advantage, US-based production facilities of several drugmakers and uncertainty over how and when the tariffs will be implemented.
Zebra mussel DNA detected in Utah’s Colorado River for first time, raising alarm over invasive species threat across the Upper Colorado River basin
For the first time, Zebra mussel DNA has been found in Utah’s Colorado River, raising alarms among wildlife officials. This finding follows a serious infestation documented near Loma, Colorado, in 2025. Concern is mounting over the potential harm this invasive species could cause to local ecosystems and infrastructure. Boaters are strongly encouraged to clean, drain,…